LS Investment Advisors LLC decreased its stake in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 9.3% during the first quarter, Holdings Channel reports. The institutional investor owned 1,957 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. LS Investment Advisors LLC’s holdings in Eagle Pharmaceuticals were worth $99,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of EGRX. Park West Asset Management LLC increased its holdings in shares of Eagle Pharmaceuticals by 41.6% in the 4th quarter. Park West Asset Management LLC now owns 1,050,000 shares of the specialty pharmaceutical company’s stock worth $42,304,000 after buying an additional 308,574 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Eagle Pharmaceuticals by 2,385.0% in the 4th quarter. Millennium Management LLC now owns 284,753 shares of the specialty pharmaceutical company’s stock worth $11,473,000 after buying an additional 273,294 shares during the last quarter. Norges Bank bought a new position in shares of Eagle Pharmaceuticals in the 4th quarter worth $10,948,000. WINTON GROUP Ltd bought a new position in shares of Eagle Pharmaceuticals during the 4th quarter valued at $9,552,000. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Eagle Pharmaceuticals by 121.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 285,318 shares of the specialty pharmaceutical company’s stock valued at $11,495,000 after purchasing an additional 156,499 shares during the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts recently commented on EGRX shares. ValuEngine raised shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Royal Bank of Canada set a $66.00 target price on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 1st. BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 5th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $58.00 target price on shares of Eagle Pharmaceuticals in a report on Thursday, February 28th. Finally, Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a report on Friday, January 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $65.17.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its earnings results on Thursday, February 28th. The specialty pharmaceutical company reported $0.86 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.07. Eagle Pharmaceuticals had a net margin of 14.96% and a return on equity of 17.76%. The company had revenue of $56.05 million for the quarter, compared to analyst estimates of $54.17 million. During the same quarter last year, the firm earned $1.05 EPS. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. Research analysts expect that Eagle Pharmaceuticals Inc will post 1.88 earnings per share for the current year.
In related news, CEO Scott Tarriff sold 24,428 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $51.17, for a total transaction of $1,249,980.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 28.20% of the stock is currently owned by company insiders.
Eagle Pharmaceuticals Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Recommended Story: How a Back-End Load Mutual Fund Works
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.